Perseus Proteomics Inc.

The University of Tokyo

University of Miyazaki

Fujita Health University

Katsushi Kouda

Keisuke Ishii

Katsuyuki Mitomo

Yoko Kayukawa

Lilin Zhang

Keiko Katsumi

Tadashi Matsuura

Hiroyuki Aburatani

Hiroshi Onishi

Fumiko Nomura

Aya Sakamoto

Yoshikazu Kurosawa

Gene Kurosawa

Kazuhiro Morishita

Yoshinori Ukai

Yukio Sudo

Kazuko Kaneda

It is an object of the present invention to provide an anti-ITGA6/B4 human antibody, which specifically recognizes ITGA6B4 complex expressed on a cell membrane and inhibits the adhesion of the ITGA6B4 complex to laminin, so as to inhibit adhesion of cancer cells to a bone marrow niche, and which is also capable of remarkably enhancing the effects of an anticancer agent on an anticancer agent resistant strain. The present invention provides an antibody against integrin A6B4, wherein the antibody specifically recognizes a human integrin A6B4 complex and inhibits intercellular adhesion.

Antibody which specifically reacts with human integrin A6B4

It is an object of the present invention to provide a drug conjugate comprising an anti-CDH3 antibody that efficiently kills cancer cells expressing CDH3. According to the present invention, there is provided an immune complex formed by binding an antibody against CDH3 or a fragment thereof having CDH3 binding ability to a chemotherapeutic agent.

Drug conjugate comprising anti-CDH3 (P-cadherin) antibody

The present invention provides an anti-CDH3 humanized antibody having lower immunogenicity, and an anti-CDH3 humanized antibody drug conjugate having the aforementioned anti-CDH3 humanized antibody. The present invention provides a conjugate of an anti-CDH3 humanized antibody and a drug by conjugating a drug having cytotoxicity to an anti-CDH3 humanized antibody having complementarity determining region sequences derived from the heavy chain variable region of an antibody produced by cells having Accession No. NITE BP-1536, and complementarity determining region sequences derived from the light chain variable region thereof, and which also comprises a heavy chain human subgroup III consensus framework sequence or a human germline sequence selected under optimal alignment as a framework region sequence of the heavy chain variable region, and a light chain human &#x3ba; subgroup I consensus framework sequence or a human germline sequence selected under optimal alignment as a framework region sequence of the light chain variable region.

Anti-CDH3 humanized antibody, drug conjugate thereof, and use thereof

It is an object of the present invention to provide an anti-cadherin antibody having a high internalization capacity and provide an anti-cadherin antibody-drug conjugate that effectively kills cadherin-expressing cancer cells with the use of such antibody. The present invention provides an anti-cadherin antibody which recognizes a cadherin domain 1 (EC1) of cadherin and exhibits a high internalization capacity.

Anti-CDH3 antibody having high internalization capacity

It is an object to provide a recombinant antibody that is an anti-CDH3 antibody having cytotoxicity on CDH3-expressing cells, which is anticipated to have fewer side effects than antibodies derived from animals other than humans and to maintain its therapeutic effects for a long period of time. The present invention provides a recombinant antibody which specifically reacts with an epitope existing in the amino acids at positions 108 to 131 or at positions 551 to 654 of the amino acid sequence shown in SEQ ID NO: 38 that is the extracellular region of human CDH3, and has cytotoxicity against CDH3-expressing cells.

Anti-human P-cadherin (CDH3) recombinant antibody

It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 &#x3bc;g/mL is 30% or more.

Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo

Growing community of inventors

Tokyo, Japan

Katsushi Kouda